Does the publication of NICE guidelines for venous thromboembolism chemical prophylaxis influence the prescribing patterns of UK hip and knee surgeons?

INTRODUCTION

We assessed the practice of surgeons regarding venous thromboembolism (VTE) chemical prophylaxis for total hip replacement (THR) and total knee replacement (TKR), before and after issuing of updated National Institute for Health and Care Excellence (NICE) guidance in 2018.

METHODS

A survey, circulated through the British Hip Society and regional trainee networks/collaboratives, was completed by 306 UK surgeons at 187 units. VTE chemical prophylaxis prescribing patterns for surgeons carrying out primary THR (=258) and TKR (=253) in low-risk patients was assessed after publication of 2018 NICE recommendations. Prescribing patterns before and after the NICE publication were subsequently explored.

RESULTS

Following the new guidance, 34% (=87) used low-molecular-weight heparin (LMWH) alone, 33% (=85) aspirin (commonly preceded by LMWH) and 31% (=81) direct oral anticoagulants (DOACs: with/without preceding LMWH) for THR. For TKR, 42% (=105) used aspirin (usually monotherapy), 31% (=78) LMWH alone and 27% (=68) DOAC (with/without preceding LMWH). NICE guidance changed the practice of 34% of hip surgeons and 41% of knee surgeons, with significantly increased use of aspirin preceded by LMWH for THR (before=25% vs after=73%; <0.001), and aspirin for TKR (before=18% vs after=84%; <0.001). Significantly more regimens were NICE guidance compliant after the 2018 update for THR (before=85.7% vs after=92.6%; =0.011) and TKR (before=87.0% vs after=98.8%; <0.001).

CONCLUSION

Over one-third of surveyed surgeons changed their VTE chemical prophylaxis in response to 2018 NICE recommendations, with more THR and TKR surgeons now compliant with latest NICE guidance. The major change in practice was an increased use of aspirin for VTE chemical prophylaxis.